Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
James L. Mohler, Dorothy A. Shead(University of the Witwatersrand), Maria Ho, Elizabeth R. Plimack(Fox Chase Cancer Center), Eric Rohren(Society of Nuclear Medicine and Molecular Imaging), Barry Boston(University of Tennessee System), Andrew J. Armstrong(Duke University), Richard J. Lee(La Roche College), Jonathan D. Tward(University of Utah), Julio M. Pow‐Sang(Moffitt Cancer Center), Seth A. Strope(Barnes-Jewish Hospital), Eric M. Horwitz(Fox Chase Cancer Center), Philip W. Kantoff(Convergent Science (United States)), Gary R. MacVicar(Northwestern University), Anthony V. D’Amico(Brigham and Women's Hospital), Stan Rosenfeld(Office of Patient Care Services), Mack Roach(University of California, San Francisco), David C. Miller(University of Michigan), Przemyslaw Twardowski(Saint John's Health Center), Sandy Srinivas(Stanford University), Arnold W. Malcolm(Vanderbilt University), Charles A. Enke(Susan Thompson Buffett Foundation), Patrick C. Walsh(Johns Hopkins University), Robert R. Bahnson(Fox Chase Cancer Center), Michael Kuettel, J. Erik Busby(University of Alabama at Birmingham), Mark H. Kawachi(City of Hope), Celestia S. Higano(University of British Columbia), James A. Eastham(Memorial Sloan Kettering Cancer Center), Thomas Farrington(Quincy College)
Cited by 254
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k